Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to -$604000.0.

  • Oncology Institute's Cash from Investing Activities fell 10580.66% to -$604000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.8 million, marking a year-over-year decrease of 10632.46%. This contributed to the annual value of $46.2 million for FY2024, which is 2622.77% down from last year.
  • Oncology Institute's Cash from Investing Activities amounted to -$604000.0 in Q3 2025, which was down 10580.66% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Cash from Investing Activities registered a high of $24.9 million during Q2 2023, and its lowest value of -$87.8 million during Q3 2022.
  • Its 5-year average for Cash from Investing Activities is -$1.9 million, with a median of -$607000.0 in 2021.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 913989.47% in 2022, then soared by 193642.71% in 2023.
  • Oncology Institute's Cash from Investing Activities (Quarter) stood at -$9.2 million in 2021, then crashed by 255.93% to -$32.6 million in 2022, then skyrocketed by 135.7% to $11.6 million in 2023, then tumbled by 115.09% to -$1.8 million in 2024, then surged by 65.58% to -$604000.0 in 2025.
  • Its Cash from Investing Activities was -$604000.0 in Q3 2025, compared to -$1.2 million in Q2 2025 and -$202000.0 in Q1 2025.